April 21, Tianjin Northnet News: After more than half a year of demonstration in the Tianjin Pilot Free Trade Zone, the "Report on the Pilot Test of Cell Therapy in the Tianjin Pilot Free Trade Zone" was drafted and then submitted to the Ministry of Commerce of the People’s Republic of China, and the Municipal Health The health, drug supervision, and technology departments jointly organize industry regulatory organizations to promote the admission of low- and medium-risk cell therapy products with medical technology and carry out clinical applications. Patients with related diseases can directly enjoy cell diagnosis and treatment in the Tianjin Pilot Free Trade Zone and the Joint Innovation Zone. Scientific research institutions and cell technology-related companies can also let go of research and realize clinical translational applications more quickly. Joint Power Biotechnology Co., Ltd., a subsidiary of Tianjin Anda Group, firmly seized the opportunity to focus on the world's leading technology in the regeneration and repair of autologous cartilage cells. The District Bureau of Science and Industry established contacts, introduced the company's development history, provided detailed technical materials for the project, and invited them to the company for inspection and guidance.